Mexico first country to launch Ryzodeg®
1 September 2014 | By Novo Nordisk
Novo Nordisk announced that in Mexico, as the first country in the world, Ryzodeg® is now launched and made available for people with type 2 diabetes...
List view / Grid view
News
Roche commences tender offer for InterMune, Inc. for US$74.00 per share in cash
1 September 2014 | By Roche
Roche announced that it has commenced a cash tender offer for all outstanding shares of common stock of InterMune, Inc. at a price of US$74.00 per share...
New data indicates Brilinta/Brilique™ has the flexibility to be initiated pre-hospital or in hospital in STEMI patients
1 September 2014 | By AstraZeneca
Results are in line with new ESC/EACTS 2014 Guidelines on Myocardial Revascularisation which give a class I recommendation to start dual antiplatelet therapy in STEMI patients at first medical contact...
Boehringer Ingelheim to present comprehensive data supporting broad respiratory portfolio in COPD, asthma and IPF at ERS 2014
1 September 2014 | By Boehringer Ingelheim
The European Respiratory Society International Congress, in Munich, Germany, September 6-10, 2014 sets the scene for important announcements across the substantial Boehringer Ingelheim respiratory portfolio...
Pfizer and Protalix BioTherapeutics announce FDA approval of pediatric Indication for ELELYSO™ (taliglucerase alfa) for injection
29 August 2014 | By Pfizer
...for intravenous use for the treatment of type 1 Gaucher disease.
Daiichi Sankyo announces cooperative sales agreement for the recombinant adsorbed hepatitis B vaccine “Bimmugen®”
28 August 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced that it has signed a cooperative sales agreement with The Chemo-Sero-Therapeutic Research Institute on August 22 for its recombinant adsorbed hepatitis B vaccine (yeast-derived), Bimmugen®...
Ebola vaccine trials fast-tracked by international consortium
28 August 2014 | By GlaxoSmithKline
Unprecedented international consortium assembled to accelerate collaborative multi-site trials of candidate Ebola vaccine...
Pfizer’s investigational vaccine candidate for Clostridium difficile receives U.S. Food and Drug Administration Fast Track designation
28 August 2014 | By Pfizer
Pfizer Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation to the company’s investigational Clostridium difficile vaccine candidate (PF-06425090). Currently in Phase 2 clinical development, the vaccine candidate is designed to prevent C...
Amgen announces positive top-line results from Phase 3 YUKAWA-2 trial of evolocumab
28 August 2014 | By Amgen
...in combination with statins in Japanese patients with high cardiovascular risk and high cholesterol.
Pfizer and Merck to collaborate on study evaluating novel anti-cancer combination regimen
27 August 2014 | By Pfizer
Pfizer Inc. and Merck & Co. Inc. through a subsidiary, announced that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s crizotinib (XALKORI®) with Merck’s investigational anti-PD-1 antibody pembrolizumab...
European Commission approves Bristol-Myers Squibb’s Daklinza (daclatasvir) across multiple genotypes for the treatment of chronic hepatitis C infection
27 August 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced that the European Commission has approved Daklinza (daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor (in vitro), for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus infection in adults...
Novo Nordisk buys production plant in New Hampshire
27 August 2014 | By Novo Nordisk
Novo Nordisk announced the acquisition of a manufacturing facility in West Lebanon, New Hampshire, USA, from Olympus Biotech...
GSK receives FDA approval of an additional Promacta® (eltrombopag) indication for use in patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST)
27 August 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the once-daily use of Promacta® (eltrombopag) in patients with severe aplastic anaemia who have had an insufficient response to immunosuppressive therapy...
Tecan and RECIPE announce co-marketing agreement for automation of LC-MSMS IVD kits
26 August 2014 | By kdm communications
With clinical laboratories increasingly turning to high throughput LC-MSMS analysis, laboratory automation specialist Tecan and RECIPE Chemicals and Instruments GmbH have announced a co-marketing agreement for automation of LC-MSMS IVD kits...
Roche and InterMune reach definitive merger agreement
26 August 2014 | By Roche
Roche and InterMune, Inc. announced they have entered into a definitive merger agreement for Roche to fully acquire InterMune at a price of US$ 74.00 per share in an all-cash transaction...
